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Artemisinin is an antimalarial lactone derived from qing hao (Artemisia annua or sweet 
wormwood). The medicinal value of this plant has 
been known to the Chinese for at least 2,000 years. 
In 1596, Li Shizhen recommended tea made from 
qing hao specifically to treat malaria symptoms. 
The genus name is derived from the Greek god-
dess Artemis and, more specifically, may have been 
named after Queen Artemisia II of Caria, a botanist 
and medical researcher in the fourth century BCE.
Artemisinin [ahr″tə-mis′ĭ-nin]
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